Weight-loss Effects aNd absorption of Direct oral anticoagulants in roux-en-Y gastric bypass patients: a prospective study (WENDY)

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519737-30-00

Enrollment

Registered

2025-05-26

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Roux-en-Y gastric bypass

Brief summary

Area under the curve (AUC) of anti-Xa levels comparing at multiple timepoints: baseline (prior to surgery), +/-17 days untill 60days after surgery, +/-3 months after surgery

Detailed description

Measured weight and BMI at follow-up visit +3 months in relation to AUC anti-Xa difference, Frequence of major bleeding events as defined per ISTH criteria, and incidence of VTE, including pulmonary embolism and deep vein thrombosis

Interventions

DRUGBeriplex® P/N 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

DRUGNORIT 200 mg capsules.

DRUGOndexxya 200 mg powder for solution for infusion

DRUGAPIXABAN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Area under the curve (AUC) of anti-Xa levels comparing at multiple timepoints: baseline (prior to surgery), +/-17 days untill 60days after surgery, +/-3 months after surgery	—

Secondary

Measure	Time frame
Measured weight and BMI at follow-up visit +3 months in relation to AUC anti-Xa difference, Frequence of major bleeding events as defined per ISTH criteria, and incidence of VTE, including pulmonary embolism and deep vein thrombosis	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026